Wave Life Sciences Stock Today

WVE Stock  USD 10.99  0.32  2.83%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 10

 
High
 
Low
Low
Wave Life is trading at 10.99 as of the 18th of January 2025, a 2.83 percent decrease since the beginning of the trading day. The stock's lowest day price was 10.96. Wave Life has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 29th of January 2023 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of November 2015
Category
Healthcare
Classification
Health Care
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company was incorporated in 2012 and is based in Singapore. The company has 152.52 M outstanding shares of which 8.21 M shares are at this time shorted by investors with about 7.85 days to cover. More on Wave Life Sciences

Moving together with Wave Stock

  0.63VANI Vivani MedicalPairCorr

Moving against Wave Stock

  0.4SRZNW Surrozen WarrantPairCorr
  0.38A Agilent TechnologiesPairCorr
  0.32DRTS Alpha Tau MedicalPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Wave Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentMD MBA
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.390.37
Notably Up
Slightly volatile
Total Current Liabilities225.1 M214.4 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total59 M47.2 M
Significantly Up
Slightly volatile
Total Assets200.5 M316.2 M
Way Down
Slightly volatile
Total Current Assets158 M270.7 M
Way Down
Slightly volatile
Debt Levels
Wave Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Wave Life's financial leverage. It provides some insight into what part of Wave Life's total assets is financed by creditors.
Liquidity
Wave Life Sciences has 32.12 M in debt with debt to equity (D/E) ratio of 1.02, which is OK given its current industry classification. Wave Life Sciences has a current ratio of 2.45, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Wave to invest in growth at high rates of return.

Free Cash Flow

(19.42 Million)
Wave Life Sciences (WVE) is traded on NASDAQ Exchange in USA. It is located in Marina One East Tower, Singapore, Singapore, 018936 and employs 266 people. Wave Life is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.73 B. Wave Life Sciences runs under Pharmaceuticals sector within Health Care industry. The entity has 152.52 M outstanding shares of which 8.21 M shares are at this time shorted by investors with about 7.85 days to cover. Wave Life Sciences has about 148.16 M in cash with (19.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Check Wave Life Probability Of Bankruptcy
Ownership Allocation
Wave Life Sciences retains a total of 152.52 Million outstanding shares. The majority of Wave Life outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Wave Life Sciences to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Wave Life Sciences. Please pay attention to any change in the institutional holdings of Wave Life Sciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Wave Ownership Details

Wave Stock Institutional Holders

InstituionRecorded OnShares
Vanguard Group Inc2024-09-30
2.9 M
Emerald Advisers, Llc2024-09-30
2.9 M
Primecap Management Company2024-09-30
2.6 M
State Street Corp2024-09-30
2.3 M
Geode Capital Management, Llc2024-09-30
2.3 M
Emerald Mutual Fund Advisers Trust2024-09-30
2.1 M
Artisan Partners Limited Partnership2024-09-30
M
Fmr Inc2024-09-30
1.5 M
Affinity Asset Advisors, Llc2024-09-30
1.4 M
Ra Capital Management, Llc2024-09-30
18.2 M
Maverick Capital Ltd2024-09-30
10 M
View Wave Life Diagnostics

Wave Life Historical Income Statement

At present, Wave Life's Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 136.8 M, whereas Selling General Administrative is forecasted to decline to about 33.7 M. View More Fundamentals

Wave Stock Against Markets

Wave Life Corporate Management

Kate RauschInvestor RelationsProfile
Stephen LakeVP DevelProfile
Linda JDSenior CounselProfile
Erik MDChief OfficerProfile
Sridhar VaddeboinaManufacturing ChemistryProfile
MBA MDCEO PresProfile
HsiuChiung YangSenior MedicineProfile

Already Invested in Wave Life Sciences?

The danger of trading Wave Life Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Wave Life is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Wave Life. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Wave Life Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Wave Life Sciences is a strong investment it is important to analyze Wave Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Wave Life's future performance. For an informed investment choice regarding Wave Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Wave Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Wave Life. If investors know Wave will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Wave Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
0.427
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.34)
Return On Equity
(2.44)
The market value of Wave Life Sciences is measured differently than its book value, which is the value of Wave that is recorded on the company's balance sheet. Investors also form their own opinion of Wave Life's value that differs from its market value or its book value, called intrinsic value, which is Wave Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Wave Life's market value can be influenced by many factors that don't directly affect Wave Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Wave Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Wave Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Wave Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.